EUVIMEDEUVIMED entdecken
Open Access

Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

Alexander H R Varey iD, Isabel Li iD, Mary-Ann El Sharouni iD, Julie Simon, Aikaterini Dedeilia, Sydney Ch'ng iD, Robyn P M Saw iD, Andrew J Spillane iD, Kerwin F Shannon, Thomas E Pennington iD, Michael Rtshiladze, Jonathan R Stretch iD und 10 weitere

Journal of Clinical Oncology · 01.04.2024 · 42 (10) · 1169-1180

DOI: 10.1200/jco.23.01020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.04.2024. Verfasst von Alexander H R Varey und 21 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Improvements in recurrence-free survival (RFS) were demonstrated in two recent randomized trials for patients with sentinel node (SN)–negative stage IIB or IIC melanoma receiving adjuvant systemic therapy (pembrolizumab/nivolumab). However, adverse events also occurred. Accurate individualized prognostic estimates of RFS and overall survival (OS) would allow patients to more accurately weigh the risks and benefits of adjuvant therapy. Since the current American Joint Committee on Cancer eighth edition (AJCC-8) melanoma staging system focuses on melanoma-specific survival, we developed a multivariable risk prediction calculator that provides estimates of 5- and 10-year RFS and OS for these patients. METHODS Data were extracted from the Melanoma Institute Australia (MIA) database for patients diagnosed with stage II (clinical or pathological) melanoma (n = 3,220). Survival prediction models were developed using multivariable Cox regression analyses (MIA models) and externally validated twice using data sets from the United States and the Netherlands. Each model's performance was assessed using C-statistics and calibration plots and compared with Cox models on the basis of AJCC-8 staging (stage models). RESULTS The 5-year and 10-year RFS C-statistics were 0.70 and 0.73 (MIA-model) versus 0.61 and 0.60 (stage-model), respectively. For OS, the 5-year and 10-year C-statistics were 0.71 and 0.75 (MIA-model) compared with 0.62 and 0.61 (stage-model), respectively. The MIA models were well calibrated and externally validated. CONCLUSION The MIA models offer accurate and personalized estimates of both RFS and OS in patients with stage II melanoma even in the absence of pathological staging with SN biopsy. These models were robust on external validations and may be used in everyday practice both with (ideally) and without performing SN biopsy to identify high-risk patients for further management strategies. An online tool will be available at the MIA website (Risk Prediction Tools).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansUnited StatesNeoplasm StagingPrognosisProportional Hazards Models

Autor:innen und Institutionen

  • Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Department of Plastic & Reconstructive Surgery, Westmead Hospital, Sydney, NSW, Australia.
  • Departments of Dermatology and Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Massachusetts General Hospital, Boston, MA.

ORCID-Profile: Alexander H R Varey, Isabel Li, Mary-Ann El Sharouni, Sydney Ch'ng, Robyn P M Saw, Andrew J Spillane, Thomas E Pennington, Jonathan R Stretch, Omgo E Nieweg, Alexander van Akkooi, Ryan J Sullivan, Genevieve M Boland, Jeffrey E Gershenwald, Paul J van Diest, Richard A Scolyer, Georgina V Long, John F Thompson, Serigne N Lo

Förderung

  • NCI NIH HHS

Zitieren

APA

Varey, A. H. R., Li, I., El Sharouni, M. A., Simon, J., Dedeilia, A., Ch'ng, S., Saw, R. P. M., Spillane, A. J., Shannon, K. F., Pennington, T. E., Rtshiladze, M., Stretch, J. R., Nieweg, O. E., van Akkooi, A., Sullivan, R. J., Boland, G. M., Gershenwald, J. E., van Diest, P. J., Scolyer, R. A., …, & Lo, S. N. (2024). Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. Journal of Clinical Oncology, 42(10), 1169-1180. https://doi.org/10.1200/jco.23.01020

Vancouver

Varey AHR, Li I, El Sharouni MA, Simon J, Dedeilia A, Ch'ng S, et al. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. Journal of Clinical Oncology. 2024;42(10):1169-1180. doi:10.1200/jco.23.01020

BibTeX
@article{Varey2024,
  author = {Varey, Alexander H R and Li, Isabel and El Sharouni, Mary-Ann and Simon, Julie and Dedeilia, Aikaterini and Ch'ng, Sydney and Saw, Robyn P M and Spillane, Andrew J and Shannon, Kerwin F and Pennington, Thomas E and Rtshiladze, Michael and Stretch, Jonathan R and Nieweg, Omgo E and van Akkooi, Alexander and Sullivan, Ryan J and Boland, Genevieve M and Gershenwald, Jeffrey E and van Diest, Paul J and Scolyer, Richard A and Long, Georgina V and Thompson, John F and Lo, Serigne N},
  title = {Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {10},
  pages = {1169--1180},
  doi = {10.1200/jco.23.01020}
}
Kostenlos starten →